Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-04-18

AUTHORS

Pierre Johansen, Barrie Chubb, Barnaby Hunt, Samuel J. P. Malkin, Anna Sandberg, Matthew Capehorn

ABSTRACT

IntroductionOnce-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than the GLP-1 RA once-daily liraglutide 1.2 mg in the SUSTAIN 10 trial. The present analysis aimed to evaluate the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus once-daily liraglutide 1.2 mg from a UK healthcare payer perspective.MethodsLong-term outcomes were projected using the IQVIA CORE Diabetes Model (version 9.0), with baseline characteristics and treatment effects sourced from SUSTAIN 10. Patients were assumed to initiate treatment with GLP-1 RAs and continue treatment until HbA1c exceeded 7.5%, at which point GLP-1 RAs were discontinued and basal insulin was initiated. Pharmacy costs and costs of complications were measured in 2018 pounds sterling (GBP), with future costs and outcomes discounted at 3.5% per annum. Utilities were taken from published sources.ResultsIn the base-case analysis, once-weekly semaglutide 1 mg was associated with an increase in discounted life expectancy of 0.21 years and discounted quality-adjusted life expectancy of 0.30 quality-adjusted life-years, compared with once-daily liraglutide 1.2 mg. Clinical benefits were achieved at reduced costs, with lifetime cost savings of GBP 140 per patient with semaglutide versus liraglutide, owing to a reduction in diabetes-related complications, in particular cardiovascular disease (mean cost saving of GBP 279 per patient). Therefore, once-weekly semaglutide 1 mg was dominant compared with once-daily liraglutide 1.2 mg. The results of the sensitivity analyses were similar, demonstrating the robustness of the base-case analysis.ConclusionsOnce-weekly semaglutide 1 mg is a cost-effective treatment option versus once-daily liraglutide 1.2 mg, based on the SUSTAIN 10 trial, from a UK healthcare payer perspective. More... »

PAGES

2427-2441

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-020-01337-7

DOI

http://dx.doi.org/10.1007/s12325-020-01337-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1126788365

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32306244


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Weight", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Complications", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucagon-Like Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycated Hemoglobin A", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liraglutide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Models, Econometric", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality-Adjusted Life Years", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johansen", 
        "givenName": "Pierre", 
        "id": "sg:person.0702626626.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702626626.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chubb", 
        "givenName": "Barrie", 
        "id": "sg:person.01067301036.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067301036.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications GmbH, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications GmbH, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hunt", 
        "givenName": "Barnaby", 
        "id": "sg:person.01346701147.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Ossian Health Economics and Communications GmbH, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Ossian Health Economics and Communications GmbH, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Malkin", 
        "givenName": "Samuel J. P.", 
        "id": "sg:person.012067446720.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novo Nordisk A/S, S\u00f8borg, Denmark", 
          "id": "http://www.grid.ac/institutes/grid.425956.9", 
          "name": [
            "Novo Nordisk A/S, S\u00f8borg, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sandberg", 
        "givenName": "Anna", 
        "id": "sg:person.016340603465.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016340603465.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Rotherham Institute for Obesity, Rotherham, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Rotherham Institute for Obesity, Rotherham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Capehorn", 
        "givenName": "Matthew", 
        "id": "sg:person.015012775345.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015012775345.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s13300-018-0542-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1110449103", 
          "https://doi.org/10.1007/s13300-018-0542-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1477-7525-11-90", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013049175", 
          "https://doi.org/10.1186/1477-7525-11-90"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-00736-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1123313018", 
          "https://doi.org/10.1007/s13300-019-00736-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-019-0630-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1114500568", 
          "https://doi.org/10.1007/s13300-019-0630-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-004-1527-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036304902", 
          "https://doi.org/10.1007/s00125-004-1527-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0371-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100859051", 
          "https://doi.org/10.1007/s13300-018-0371-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-04-18", 
    "datePublishedReg": "2020-04-18", 
    "description": "IntroductionOnce-weekly semaglutide 1\u00a0mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type\u00a02 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than the GLP-1 RA once-daily liraglutide 1.2\u00a0mg in the SUSTAIN\u00a010 trial. The present analysis aimed to evaluate the long-term cost-effectiveness of once-weekly semaglutide 1\u00a0mg versus once-daily liraglutide 1.2\u00a0mg from a UK healthcare payer perspective.MethodsLong-term outcomes were projected using the IQVIA CORE Diabetes Model (version\u00a09.0), with baseline characteristics and treatment effects sourced from SUSTAIN\u00a010. Patients were assumed to initiate treatment with GLP-1 RAs and continue treatment until HbA1c exceeded 7.5%, at which point GLP-1 RAs were discontinued and basal insulin was initiated. Pharmacy costs and costs of complications were measured in 2018\u00a0pounds sterling (GBP), with future costs and outcomes discounted at 3.5% per annum. Utilities were taken from published sources.ResultsIn the base-case analysis, once-weekly semaglutide 1\u00a0mg was associated with an increase in discounted life expectancy of 0.21\u00a0years and discounted quality-adjusted life expectancy of 0.30\u00a0quality-adjusted life-years, compared with once-daily liraglutide 1.2\u00a0mg. Clinical benefits were achieved at reduced costs, with lifetime cost savings of GBP\u00a0140 per patient with semaglutide versus liraglutide, owing to a reduction in diabetes-related complications, in particular cardiovascular disease (mean cost saving of GBP\u00a0279 per patient). Therefore, once-weekly semaglutide 1\u00a0mg was dominant compared with once-daily liraglutide 1.2\u00a0mg. The results of the sensitivity analyses were similar, demonstrating the robustness of the base-case analysis.ConclusionsOnce-weekly semaglutide 1\u00a0mg is a cost-effective treatment option versus once-daily liraglutide 1.2\u00a0mg, based on the SUSTAIN\u00a010 trial, from a UK healthcare payer perspective.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-020-01337-7", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "keywords": [
      "GLP-1 RAs", 
      "weekly semaglutide 1", 
      "liraglutide 1.2", 
      "UK healthcare payer perspective", 
      "healthcare payer perspective", 
      "base-case analysis", 
      "payer perspective", 
      "novel glucagon-like peptide-1 receptor agonist", 
      "glucagon-like peptide-1 receptor agonists", 
      "peptide-1 receptor agonists", 
      "cost-effective treatment option", 
      "diabetes-related complications", 
      "cost of complications", 
      "life expectancy", 
      "type 2 diabetes", 
      "treatment of type", 
      "quality-adjusted life expectancy", 
      "lifetime cost savings", 
      "particular cardiovascular disease", 
      "daily liraglutide", 
      "baseline characteristics", 
      "basal insulin", 
      "clinical benefit", 
      "pharmacy costs", 
      "treatment options", 
      "receptor agonist", 
      "IQVIA CORE", 
      "cardiovascular disease", 
      "body weight", 
      "liraglutide", 
      "greater reduction", 
      "treatment effects", 
      "complications", 
      "patients", 
      "treatment", 
      "pounds sterling", 
      "trials", 
      "outcomes", 
      "expectancy", 
      "long term", 
      "RA", 
      "semaglutide", 
      "diabetes", 
      "cost savings", 
      "agonists", 
      "insulin", 
      "ResultsIn", 
      "disease", 
      "hemoglobin", 
      "Versus", 
      "future costs", 
      "reduction", 
      "options", 
      "years", 
      "present analysis", 
      "reduced costs", 
      "analysis", 
      "weight", 
      "sensitivity analysis", 
      "benefits", 
      "increase", 
      "sustain", 
      "effect", 
      "utility", 
      "UK", 
      "annum", 
      "sterling", 
      "types", 
      "cost", 
      "results", 
      "characteristics", 
      "perspective", 
      "model", 
      "source", 
      "savings", 
      "core", 
      "Gbps", 
      "robustness"
    ], 
    "name": "Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK", 
    "pagination": "2427-2441", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1126788365"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-020-01337-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32306244"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-020-01337-7", 
      "https://app.dimensions.ai/details/publication/pub.1126788365"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_862.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-020-01337-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01337-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01337-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01337-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-020-01337-7'


 

This table displays all metadata directly associated to this object as RDF triples.

271 TRIPLES      21 PREDICATES      126 URIs      112 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-020-01337-7 schema:about N29833acd856e46d795abb16ccb70147c
2 N2d07e0ace4af42baa3f482e9cde58a91
3 N4b584296999e43a18c3d2d25009b1128
4 N4e1d4616e076458497847099d732a458
5 N53cbed764f544e4bbdef741e492aa9e8
6 N5d03f1df3dac4a6b96656583693aa6c7
7 N6137232a522e42a88e90be6e36d2ce2e
8 N700513c4b16f4304b6330ea22c6b5764
9 N7829a9f9cf90424282c806762ea4db4d
10 N7e18ffc022fc4e08bf893dc4670f8648
11 N9179a9de79eb4594b002eac065f25790
12 Na5278da081774ce19c06fa56cc2182fb
13 Nae2f07840752458eb3da1e6c10d6cdfb
14 Nbf7646d231ce403caf05e62b5d39d664
15 Nc2c5010aec904a08b82ee44a48cce5a5
16 Ndedee7eac6b64e60a6921a61f5d6681d
17 Nfa6c403e24664c5089d3b40daa242c01
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N1e8398e7cc0a4179a30a1556af1d3655
21 schema:citation sg:pub.10.1007/s00125-004-1527-z
22 sg:pub.10.1007/s13300-018-0371-y
23 sg:pub.10.1007/s13300-018-0542-x
24 sg:pub.10.1007/s13300-019-00736-6
25 sg:pub.10.1007/s13300-019-0630-6
26 sg:pub.10.1186/1477-7525-11-90
27 schema:datePublished 2020-04-18
28 schema:datePublishedReg 2020-04-18
29 schema:description IntroductionOnce-weekly semaglutide 1 mg is a novel glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes that has demonstrated significantly greater reductions in glycated haemoglobin (HbA1c) and body weight than the GLP-1 RA once-daily liraglutide 1.2 mg in the SUSTAIN 10 trial. The present analysis aimed to evaluate the long-term cost-effectiveness of once-weekly semaglutide 1 mg versus once-daily liraglutide 1.2 mg from a UK healthcare payer perspective.MethodsLong-term outcomes were projected using the IQVIA CORE Diabetes Model (version 9.0), with baseline characteristics and treatment effects sourced from SUSTAIN 10. Patients were assumed to initiate treatment with GLP-1 RAs and continue treatment until HbA1c exceeded 7.5%, at which point GLP-1 RAs were discontinued and basal insulin was initiated. Pharmacy costs and costs of complications were measured in 2018 pounds sterling (GBP), with future costs and outcomes discounted at 3.5% per annum. Utilities were taken from published sources.ResultsIn the base-case analysis, once-weekly semaglutide 1 mg was associated with an increase in discounted life expectancy of 0.21 years and discounted quality-adjusted life expectancy of 0.30 quality-adjusted life-years, compared with once-daily liraglutide 1.2 mg. Clinical benefits were achieved at reduced costs, with lifetime cost savings of GBP 140 per patient with semaglutide versus liraglutide, owing to a reduction in diabetes-related complications, in particular cardiovascular disease (mean cost saving of GBP 279 per patient). Therefore, once-weekly semaglutide 1 mg was dominant compared with once-daily liraglutide 1.2 mg. The results of the sensitivity analyses were similar, demonstrating the robustness of the base-case analysis.ConclusionsOnce-weekly semaglutide 1 mg is a cost-effective treatment option versus once-daily liraglutide 1.2 mg, based on the SUSTAIN 10 trial, from a UK healthcare payer perspective.
30 schema:genre article
31 schema:isAccessibleForFree true
32 schema:isPartOf Nba047dc2438e4d8481975dbc2e71dfef
33 Ne67e101d04a34692a407222c260cfb1b
34 sg:journal.1096634
35 schema:keywords GLP-1 RAs
36 Gbps
37 IQVIA CORE
38 RA
39 ResultsIn
40 UK
41 UK healthcare payer perspective
42 Versus
43 agonists
44 analysis
45 annum
46 basal insulin
47 base-case analysis
48 baseline characteristics
49 benefits
50 body weight
51 cardiovascular disease
52 characteristics
53 clinical benefit
54 complications
55 core
56 cost
57 cost of complications
58 cost savings
59 cost-effective treatment option
60 daily liraglutide
61 diabetes
62 diabetes-related complications
63 disease
64 effect
65 expectancy
66 future costs
67 glucagon-like peptide-1 receptor agonists
68 greater reduction
69 healthcare payer perspective
70 hemoglobin
71 increase
72 insulin
73 life expectancy
74 lifetime cost savings
75 liraglutide
76 liraglutide 1.2
77 long term
78 model
79 novel glucagon-like peptide-1 receptor agonist
80 options
81 outcomes
82 particular cardiovascular disease
83 patients
84 payer perspective
85 peptide-1 receptor agonists
86 perspective
87 pharmacy costs
88 pounds sterling
89 present analysis
90 quality-adjusted life expectancy
91 receptor agonist
92 reduced costs
93 reduction
94 results
95 robustness
96 savings
97 semaglutide
98 sensitivity analysis
99 source
100 sterling
101 sustain
102 treatment
103 treatment effects
104 treatment of type
105 treatment options
106 trials
107 type 2 diabetes
108 types
109 utility
110 weekly semaglutide 1
111 weight
112 years
113 schema:name Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
114 schema:pagination 2427-2441
115 schema:productId N1d3bd5bf2a244b8a88b74bbc242c6ac8
116 Nc4d9a6d8d6b744588264f7faa0eee3a1
117 Ne900d3a77cf340829ef3fd0b09d6db7c
118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1126788365
119 https://doi.org/10.1007/s12325-020-01337-7
120 schema:sdDatePublished 2022-12-01T06:41
121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
122 schema:sdPublisher N7e8c61dfc2654ad6b58f7e0c3ff8f7b8
123 schema:url https://doi.org/10.1007/s12325-020-01337-7
124 sgo:license sg:explorer/license/
125 sgo:sdDataset articles
126 rdf:type schema:ScholarlyArticle
127 N1d3bd5bf2a244b8a88b74bbc242c6ac8 schema:name pubmed_id
128 schema:value 32306244
129 rdf:type schema:PropertyValue
130 N1e8398e7cc0a4179a30a1556af1d3655 rdf:first sg:person.0702626626.45
131 rdf:rest Nf56d7acbd7bb418998d1a377b3561203
132 N29833acd856e46d795abb16ccb70147c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 N2d07e0ace4af42baa3f482e9cde58a91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Glycated Hemoglobin A
137 rdf:type schema:DefinedTerm
138 N4b584296999e43a18c3d2d25009b1128 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Liraglutide
140 rdf:type schema:DefinedTerm
141 N4e1d4616e076458497847099d732a458 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Drug Administration Schedule
143 rdf:type schema:DefinedTerm
144 N53cbed764f544e4bbdef741e492aa9e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Diabetes Complications
146 rdf:type schema:DefinedTerm
147 N5d03f1df3dac4a6b96656583693aa6c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Diabetes Mellitus, Type 2
149 rdf:type schema:DefinedTerm
150 N6137232a522e42a88e90be6e36d2ce2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Hypoglycemic Agents
152 rdf:type schema:DefinedTerm
153 N700513c4b16f4304b6330ea22c6b5764 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Female
155 rdf:type schema:DefinedTerm
156 N73ac77a862fa4efc9152e9229ced90cb rdf:first sg:person.015012775345.30
157 rdf:rest rdf:nil
158 N7829a9f9cf90424282c806762ea4db4d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Cost-Benefit Analysis
160 rdf:type schema:DefinedTerm
161 N7e18ffc022fc4e08bf893dc4670f8648 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Aged
163 rdf:type schema:DefinedTerm
164 N7e8c61dfc2654ad6b58f7e0c3ff8f7b8 schema:name Springer Nature - SN SciGraph project
165 rdf:type schema:Organization
166 N9179a9de79eb4594b002eac065f25790 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Quality-Adjusted Life Years
168 rdf:type schema:DefinedTerm
169 N9cf4e15dbb1d4809b43e0f071ecca908 rdf:first sg:person.012067446720.22
170 rdf:rest Nf7dccba25cde4551b26b1b27163b2e73
171 Na5278da081774ce19c06fa56cc2182fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Middle Aged
173 rdf:type schema:DefinedTerm
174 Nae2f07840752458eb3da1e6c10d6cdfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Male
176 rdf:type schema:DefinedTerm
177 Nba047dc2438e4d8481975dbc2e71dfef schema:issueNumber 5
178 rdf:type schema:PublicationIssue
179 Nbd0f7edf64864eda8ea14fc1b5c49556 rdf:first sg:person.01346701147.33
180 rdf:rest N9cf4e15dbb1d4809b43e0f071ecca908
181 Nbf7646d231ce403caf05e62b5d39d664 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Body Weight
183 rdf:type schema:DefinedTerm
184 Nc2c5010aec904a08b82ee44a48cce5a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Glucagon-Like Peptides
186 rdf:type schema:DefinedTerm
187 Nc4d9a6d8d6b744588264f7faa0eee3a1 schema:name dimensions_id
188 schema:value pub.1126788365
189 rdf:type schema:PropertyValue
190 Ndedee7eac6b64e60a6921a61f5d6681d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name United Kingdom
192 rdf:type schema:DefinedTerm
193 Ne67e101d04a34692a407222c260cfb1b schema:volumeNumber 37
194 rdf:type schema:PublicationVolume
195 Ne900d3a77cf340829ef3fd0b09d6db7c schema:name doi
196 schema:value 10.1007/s12325-020-01337-7
197 rdf:type schema:PropertyValue
198 Nf56d7acbd7bb418998d1a377b3561203 rdf:first sg:person.01067301036.89
199 rdf:rest Nbd0f7edf64864eda8ea14fc1b5c49556
200 Nf7dccba25cde4551b26b1b27163b2e73 rdf:first sg:person.016340603465.00
201 rdf:rest N73ac77a862fa4efc9152e9229ced90cb
202 Nfa6c403e24664c5089d3b40daa242c01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Models, Econometric
204 rdf:type schema:DefinedTerm
205 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
206 schema:name Medical and Health Sciences
207 rdf:type schema:DefinedTerm
208 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
209 schema:name Clinical Sciences
210 rdf:type schema:DefinedTerm
211 sg:journal.1096634 schema:issn 0741-238X
212 1865-8652
213 schema:name Advances in Therapy
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01067301036.89 schema:affiliation grid-institutes:grid.425956.9
217 schema:familyName Chubb
218 schema:givenName Barrie
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067301036.89
220 rdf:type schema:Person
221 sg:person.012067446720.22 schema:affiliation grid-institutes:None
222 schema:familyName Malkin
223 schema:givenName Samuel J. P.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012067446720.22
225 rdf:type schema:Person
226 sg:person.01346701147.33 schema:affiliation grid-institutes:None
227 schema:familyName Hunt
228 schema:givenName Barnaby
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346701147.33
230 rdf:type schema:Person
231 sg:person.015012775345.30 schema:affiliation grid-institutes:None
232 schema:familyName Capehorn
233 schema:givenName Matthew
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015012775345.30
235 rdf:type schema:Person
236 sg:person.016340603465.00 schema:affiliation grid-institutes:grid.425956.9
237 schema:familyName Sandberg
238 schema:givenName Anna
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016340603465.00
240 rdf:type schema:Person
241 sg:person.0702626626.45 schema:affiliation grid-institutes:grid.425956.9
242 schema:familyName Johansen
243 schema:givenName Pierre
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0702626626.45
245 rdf:type schema:Person
246 sg:pub.10.1007/s00125-004-1527-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036304902
247 https://doi.org/10.1007/s00125-004-1527-z
248 rdf:type schema:CreativeWork
249 sg:pub.10.1007/s13300-018-0371-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1100859051
250 https://doi.org/10.1007/s13300-018-0371-y
251 rdf:type schema:CreativeWork
252 sg:pub.10.1007/s13300-018-0542-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1110449103
253 https://doi.org/10.1007/s13300-018-0542-x
254 rdf:type schema:CreativeWork
255 sg:pub.10.1007/s13300-019-00736-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1123313018
256 https://doi.org/10.1007/s13300-019-00736-6
257 rdf:type schema:CreativeWork
258 sg:pub.10.1007/s13300-019-0630-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1114500568
259 https://doi.org/10.1007/s13300-019-0630-6
260 rdf:type schema:CreativeWork
261 sg:pub.10.1186/1477-7525-11-90 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013049175
262 https://doi.org/10.1186/1477-7525-11-90
263 rdf:type schema:CreativeWork
264 grid-institutes:None schema:alternateName Ossian Health Economics and Communications GmbH, Basel, Switzerland
265 Rotherham Institute for Obesity, Rotherham, UK
266 schema:name Ossian Health Economics and Communications GmbH, Basel, Switzerland
267 Rotherham Institute for Obesity, Rotherham, UK
268 rdf:type schema:Organization
269 grid-institutes:grid.425956.9 schema:alternateName Novo Nordisk A/S, Søborg, Denmark
270 schema:name Novo Nordisk A/S, Søborg, Denmark
271 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...